SAB Ebitda from 2010 to 2024

SABS Stock  USD 4.08  0.23  5.97%   
SAB Biotherapeutics EBITDA yearly trend continues to be comparatively stable with very little volatility. EBITDA is likely to outpace its year average in 2024. From the period from 2010 to 2024, SAB Biotherapeutics EBITDA quarterly data regression had r-value of (0.40) and coefficient of variation of (123.33). View All Fundamentals
 
EBITDA  
First Reported
2010-12-31
Previous Quarter
-38.1 M
Current Value
-36.2 M
Quarterly Volatility
13.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check SAB Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among SAB Biotherapeutics' main balance sheet or income statement drivers, such as Interest Income of 80.1 K, Depreciation And Amortization of 2.1 M or Interest Expense of 289.4 K, as well as many indicators such as Price To Sales Ratio of 16.12, Dividend Yield of 0.0 or PTB Ratio of 0.7. SAB financial statements analysis is a perfect complement when working with SAB Biotherapeutics Valuation or Volatility modules.
  
Check out the analysis of SAB Biotherapeutics Correlation against competitors.
For more information on how to buy SAB Stock please use our How to Invest in SAB Biotherapeutics guide.

Latest SAB Biotherapeutics' Ebitda Growth Pattern

Below is the plot of the Ebitda of SAB Biotherapeutics over the last few years. It is SAB Biotherapeutics' EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in SAB Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
Ebitda10 Years Trend
Slightly volatile
   Ebitda   
       Timeline  

SAB Ebitda Regression Statistics

Arithmetic Mean(10,819,236)
Geometric Mean11,426,210
Coefficient Of Variation(123.33)
Mean Deviation7,707,020
Median(8,234,406)
Standard Deviation13,343,897
Sample Variance178.1T
Range59.2M
R-Value(0.40)
Mean Square Error161T
R-Squared0.16
Significance0.14
Slope(1,195,857)
Total Sum of Squares2492.8T

SAB Ebitda History

2024-36.2 M
2023-38.1 M
2022-15.1 M
2021-11.7 M
202021.1 M

About SAB Biotherapeutics Financial Statements

SAB Biotherapeutics shareholders use historical fundamental indicators, such as Ebitda, to determine how well the company is positioned to perform in the future. Although SAB Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in SAB Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on SAB Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
EBITDA-38.1 M-36.2 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for SAB Stock Analysis

When running SAB Biotherapeutics' price analysis, check to measure SAB Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SAB Biotherapeutics is operating at the current time. Most of SAB Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of SAB Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SAB Biotherapeutics' price. Additionally, you may evaluate how the addition of SAB Biotherapeutics to your portfolios can decrease your overall portfolio volatility.